42 results about "Peripheral plasma" patented technology

Disclosed is a multi-inductively coupled plasma reactor and method thereof. In a multi-inductively coupled plasma reacting method, an etching method to increase a specific portion of a substrate to be processed includes etching a specific portion of a substrate to be processed; and depositing a passivation layer on a surface of the specific portion etched, wherein the etching and depositing steps are repeatedly proceeded, and one of both steps is executed when there is plasma formed by a central plasma source and a peripheral plasma source. According to the multi-inductively coupled plasma reactor and method thereof of the invention, it is possible that plasma is uniformly processed on the entire area of the substrate since the central plasma source and the peripheral source are provided separately. Further, it is possible to form an independent multiple plasma area without electrical interference in the plasma reactor using the interference prevention electrode grounded between the central plasma source and the peripheral plasma source. Further, the plasma formed by the central plasma source and the peripheral plasma source is used to deeply etch a specific portion of the substrate to be processed.

A plasma processing apparatus includes a worktable in a process chamber to horizontally place a target substrate thereon. A plasma generation space is defined above and around the worktable within the process chamber. The plasma generation space includes a peripheral plasma region and a main plasma region respectively located outside and inside an outer edge of the target substrate placed on the worktable. The apparatus further includes a magnetic field forming mechanism configured to form a magnetic field within the peripheral plasma region. The magnetic field includes magnetic force lines extending through the peripheral plasma region between a start position and an end position, at least one of which is located radially inside a sidewall of the process chamber.

The invention discloses a method for improving a proportion of fetal free DNA in a maternal plasma free DNA sequencing library. The method comprises the following steps: extracting maternal plasma free DNA; adding specific sequence tags at two ends of the maternal plasma free DNA so as to obtain plasma free DNA with maternal individual identification markings; subjecting the plasma free DNA with the maternal individual identification markings to PCR amplification so as to obtain an original library of maternal individual plasma free DNA; and recovering the maternal original library in a selected length range so as to obtain a recovered library used for high-throughput sequencing, or mixing the maternal original libraries of a plurality of different individual pregnant women so as to build the recovered library. The method provided by the invention can accurately detect a sample with excessively low content of maternal peripheral plasma fetal free DNA, reduces the sequencing data volume of every sample, improves the sample throughput of a sequencing reaction, reduces detection cost, and facilitates large-scale popularization.

The invention provides a method for monitoring secondary drug resistance of a lung cancer patient to a tyrosine kinase inhibitor through ddPCR technology, and an application of the method to monitoring and control of the tyrosine kinase inhibitor in a process of treating a lung cancer patient. The method comprises: firstly, extracting DNA from peripheral plasma of a lung cancer patient, then detecting a mutation condition of a drug-resistant mutation site T790M of EGFR in the DNA through adoption of ddPCR technology, and finally judging whether the patient produces drug resistance according to the mutation situation.

The invention discloses a method for detecting an EGFR L858R locus in lung cancer by ddPCR and an application thereof. According to the sequence of an EGFR gene, a pair of amplified primers includingan upstream primer and a downstream primer are designed; according to the mutation sequence of L858R (2573T>G, COSM6224), a probe for detecting a wild type sequence and a probe for detecting a mutation sequence are designed. The primers and the probes are used for ddPCR and used for detecting and analyzing important loci related to targeted medication for lung cancer in ctDNA. Firstly, DNA is extracted from peripheral plasma of lung cancer patients, and the mutation condition of the mutation locus L858R of EGFR is detected by the ddPCR technology, so as to guide the patients to use drugs. Themethod can be used for diagnosis of early-stage lung cancer such as stage I, II and III A of tumor, can detect 0.0625% EGFR gene L858R mutation, and has the sensitivity reaching 10 times or more thatof conventional methods.

The invention provides a plasma miRNA biomarker related to colorectal cancer diagnosis and an application thereof, and belongs to the field of biotechnology and oncology. The plasma miRNA biomarker related to colorectal cancer diagnosis is plasma miR-21. The present study suggests that plasma miRNAs are mainly from secretion of tumor tissues or are induced by death and dissociation of tumor cells, but the miRNAs with differential expression in the tissues do not absolutely experience differential expression in the plasma, and some miRNAs are even reverse. Although the miR-21 has been determined to be capable of being used as the marker in colorectal cancer tissues, results in the reports of peripheral plasma samples are not uniform, the innovation of the invention lies in that the expression trend uniformity of the plasma miR-21 and the tissue miR-21 is determined, the plasma miR-21 can be used as a diagnostic marker and is non-invasive, so that the plasma miR-21 can be applied to future clinic.

The invention provides a method for detecting absolute copy number of fetal free DNA in maternal plasma on basis of digital PCR. The method for detecting the absolute copy number of the fetal free DNAin the maternal plasma on basis of the digital PCR comprises the following steps: obtaining total DNA from maternal peripheral plasma, and selecting gene locus sequences and internal reference gene sequences containing maternal-fetal methylation differences for designing primers and probes; carrying out methylation-sensitive restriction endonuclease digestion; and then, performing digital PCR amplification on the gene locus sequences and the internal reference gene sequences containing the maternal-fetal methylation differences in digital PCR apparatus, detecting fluorescent signals so as toobtain the absolute copy number of the fetal free DNA in the maternal plasma, and excluding false positive interference of maternal free DNA caused by incomplete enzyme digestion. The method for detecting the absolute copy number of the fetal free DNA in the maternal plasma on basis of the digital PCR combines a methylation-sensitive restriction endonuclease digestion-PCR means and a digital PCR platform, and utilizes maternal-fetal methylation difference genes as markers for detecting the absolute copy number of the fetal free DNA in the maternal plasma, so that the method is beneficial for accurately and quickly performing early non-invasive prenatal screening or prenatal diagnosis on pregnant women.

The invention relates to a diagnostic marker for precursor Mild Cognitive Impairment (MCI) of Alzheimer's disease. The marker is plasma long-chain non-coding ribonucleic acid (lncRNA), and the plasmalncRNA comprises one or more of ENST00000549762, NR_024049, T32498 or ENST00000567919. The invention further relates to application of the marker and a corresponding kit. The MCI diagnostic marker, the MCI diagnostic kit and the corresponding detection method have the advantages that the peripheral blood lncRNA biomarker with high diagnostic value for MCI is found for the first time, the effectivemarker is provided for low-damage MCI diagnosis through peripheral plasma, and early diagnosis and early intervention of Alzheimer's disease are facilitated.

The invention discloses a microhaplotype genetic marker combination and method for noninvasive prenatal paternity relationship judgment. The microhaplotype genetic marker combination for noninvasive prenatal paternity relationship judgment is provided firstly; and a calculation model of a fetal paternity index (PI) is built based on a Bayesian principle according to a sequencing result in combination with a high-throughput sequencing technology by taking microhaplotypes uniformly distributed on autosomes as genetic markers so as to judge a prenatal paternity relationship of gemellary pregnancy. According to the method, only 10ml of peripheral blood of a mother needs to be provided, and free DNA extracted from peripheral plasma of the mother already contains free DNA of a fetus, so that themother and the fetus only need one sample. Because only the venous blood of the pregnant woman needs to be extracted, the operation is simple and convenient, and the pregnant woman and the fetus cannot be wounded; and identification can be carried out after 7 weeks of pregnancy, and a detection result is consistent with that of a conventional STR typing method, so that the application prospect isrelatively great.

The invention provides a method for monitoring and controlling drug resistance of a colorectal cancer patient to panitumumab/cetuximab through ddPCR technology, and an application of the method to monitoring and controlling of panitumumab/cetuximab in a process of treating colorectal cancer. The method comprises: firstly extracting DNA from peripheral plasma of a colorectal cancer patient, then detecting a mutation situation of a drug-resistant mutation site G13D of KRAS in the DNA through ddPCR technology, and finally judging if the patient produces drug resistance according to the mutation situation.

The invention relates to a method for identifying prenatal parental power relationship. Through cyclization amplification enlargement, only peripheral 10ul-1.2ml of plasma of a mother needs to be provided, and free DNA extracted from the peripheral plasma of the mother always contains free DNA of a foetus, so that only one part of samples of the mother and the foetus can be needed. Only the veinalblood of a pregnant woman needs to be extracted, the operation is simple and convenient, and the blood volume is small, so that the pregnant woman and the foetus cannot be damaged, and identificationcan be performed after pregnancy for 10 weeks.

The invention relates to the technical field of biological medicines. According to the invention, peripheral plasma of a patient with multiple myeloma is subjected to microRNAs expression profile analysis, and based upon qPCR technical verification, it discovers that the expression level of miR-145-3p in the peripheral plasma of the patient with the multiple myeloma is significantly reduced in comparison that in normal and healthy people. In addition, by conducting miR-145-3p over-expression and miR-145-3p silencing and by observing cell apoptosis and autophagy levels, results show that the miR-145-3p is capable of promoting cell apoptosis and autophagy. The invention provides a novel serum marker for the diagnosis of the multiple myeloma disease and also provides a novel target for the prevention and treatment of the multiple myeloma disease.

The invention discloses an antibody composition for detecting the treatment effect of multiple myeloma as well as a kit and application thereof, and the antibody composition scheme provided by the invention comprises a flow antibody combination which is never clinically used for detecting peripheral blood tumor plasma cells in the past, stipulates the number of detected cells and standard operation steps, and defines the degree to which the sensitivity needs to be reached. Peripheral blood is adopted to replace a bone marrow specimen, the pain of a patient receiving bone marrow puncture can be greatly relieved, peripheral plasma cell detection can be repeatedly operated, flexibility and convenience are achieved, the workload of clinicians is greatly relieved, and efficiency is improved.

The invention provides a method for monitoring secondary drug resistance to imatinib (Glivec)/nilotinib through ddPCR technology, and an application of the method to monitoring and control of imatinib (Glivec)/nilotinib in a process of treating chronic granulocytic leukemia. The method comprises: firstly, extracting DNA from peripheral plasma of a patient suffering from chronic granulocytic leukemia, then detecting a mutation situation of a drug-resistant mutation site T315I of an ABL gene or a drug-resistant mutation site T674I of a PDGFR[alpha] gene in the DNA through ddPCR technology, and finally judging if the patient produces drug resistance according to the mutation situation.

A person who is used in the field of medicine- Preparation of human cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type human bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, human bone marrow cells and human myeloma cells were fused into hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, Hybrid cell clones were screened by HAT, The hybridization strains of Rh positive cells which canbe expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification, A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasma of pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

The invention discloses application of SIRT5 protein as a marker in diagnosis or auxiliary diagnosis of acute myocardial infarction. Experiments prove that the expression quantity of the SIRT5 protein in the heart of a C57BL/6 mouse acute myocardial infarction model is remarkably increased compared with that of a sham-operation mouse; and compared with the peripheral plasma of the sham-operation mouse, the succinylation modification of a plurality of lysine sites of albumin and immune globulin G in the peripheral plasma of the C57BL/6 mouse acute myocardial infarction model is remarkably reduced. Therefore, the acute myocardial infarction can be diagnosed or diagnosed in an auxiliary manner by detecting the expression quantity and/or activity of the SIRT5 protein in the heart and/or the succinylation modification degree of lysine of the protein in the peripheral plasma. The application has an important application value.

The invention discloses a rapid peripheral plasma collector which comprises a collection assembly and a mounting assembly, a disinfection box is filled with disinfection alcohol cotton through an injection hole, a mounting base and an outer plastic body are screwed together in a threaded mode, the lower end of the mounting base is aligned with a finger, a handle and a force application rod are tightly pressed, and the finger is punctured after a collecting needle is pointed, then taking down the mounting base and the collecting needle, putting a capillary aligned to the bleeding position for peripheral plasma collection, keeping the handle and the force application rod are continuously pressed, blood will enter the capillary, and the peripheral plasma collection work is completed through separation of a hemofilter. The invention further discloses a use method of the rapid peripheral plasma collector, blood is collected in the capillary through a seepage plate, a stop block can be used to prevent the blood from entering the collection tube, when the handle and the force application rod are loosened, a piston moves upwards, so that negative pressure is formed in the capillary and drive the blood to flow upwards, so that blood can be filtered by the hemofilter to separate plasma and red blood cells, and the operation is simple.